Atara Biotherapeutics Files 8-K for Security Holder Vote

Ticker: ATRA · Form: 8-K · Filed: Jun 11, 2024 · CIK: 1604464

Atara Biotherapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyAtara Biotherapeutics, INC. (ATRA)
Form Type8-K
Filed DateJun 11, 2024
Risk Levellow
Pages3
Reading Time4 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: corporate-governance, shareholder-vote

Related Tickers: ATRA

TL;DR

ATRA filed an 8-K for a shareholder vote - details TBD.

AI Summary

On June 10, 2024, Atara Biotherapeutics, Inc. filed an 8-K report to announce the submission of matters to a vote of its security holders. The filing does not contain specific details about the matters to be voted on or any associated financial implications.

Why It Matters

This filing indicates that Atara Biotherapeutics is convening a meeting or seeking shareholder approval for certain corporate actions, which could impact the company's future direction.

Risk Assessment

Risk Level: low — The filing is procedural and does not disclose any new material financial information or significant corporate events.

Key Players & Entities

FAQ

What specific matters will be submitted for a vote of Atara Biotherapeutics' security holders?

The filing does not specify the exact matters to be voted on, only that matters are being submitted for a vote.

When was the earliest event reported in this 8-K filing?

The earliest event reported was on June 10, 2024.

What is Atara Biotherapeutics' Commission File Number?

Atara Biotherapeutics' Commission File Number is 001-36548.

Where are Atara Biotherapeutics' principal executive offices located?

Atara Biotherapeutics' principal executive offices are located at 2380 Conejo Spectrum St, Suite 200, Thousand Oaks, CA 91320.

What is the IRS Employer Identification Number for Atara Biotherapeutics?

The IRS Employer Identification Number for Atara Biotherapeutics is 46-0920988.

Filing Stats: 882 words · 4 min read · ~3 pages · Grade level 13 · Accepted 2024-06-10 17:32:02

Key Financial Figures

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Atara Biotherapeutics, Inc. By: /s/ Amar Murugan Amar Murugan Executive Vice President and Chief Legal Officer Date: June 10, 2024

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing